Latest Global Markets News

Regal Partners Global Investments Limited (ASX, RG1) has reported a remarkable turnaround with a $103.5 million profit after tax for the half-year ended 31 December 2025, alongside a 6.0 cent fully franked interim dividend and an active share buy-back program.

Macquarie Group reports solid 3Q26 results with robust profit growth across divisions and a strong capital surplus, underpinned by strategic technology investments and regulatory compliance.

Macquarie Group has reported a solid third quarter for FY26, with significant profit gains in asset management and capital divisions, alongside steady growth in banking services. The group maintains a strong capital buffer, positioning itself well despite a cautious economic outlook.

West Cobar Metals has confirmed that antimony grades at its Bulla Park project in NSW are higher than previously reported, thanks to a new assay method. This discovery could enhance the deposit’s value amid rising demand for critical minerals.

Paradigm Biopharmaceuticals has entered a binding agreement with AVet Health to co-develop and license a novel oral therapy for veterinary osteoarthritis in Australia and New Zealand, unlocking new market potential while advancing its human clinical trials.

CAR Group Limited has reported a strong first half for FY26, posting 13% revenue growth and reaffirming its optimistic outlook for the full year, driven by strategic AI integration and global market expansion.

CAR Group has reported strong first-half results for FY26, with double-digit revenue and earnings growth across all key regions, underpinned by strategic AI investments and expanding market presence.

Terragen Holdings has raised A$7 million through a strategic equity raising to fund scientific research and accelerate global commercialisation, while appointing Dr Michele Allan AO as its new Chair.

Fortuna Metals has confirmed it is exempt from Malawi’s 2025 raw mineral export ban, provided it processes rutile and graphite locally before export. This regulatory clarity positions the company to develop premium mineral products for high-value markets.

OFX Group Limited has initiated a strategic review to explore growth and sale options while reporting softer 3Q FY26 earnings impacted by macroeconomic challenges. The company also announced the resignation of its CFO, signaling a period of transition.

Cyclopharm Limited is accelerating its US market push for Technegas with a A$16 million capital raise following a record 2025 sales performance. The company aims to expand its US installations and advance new clinical applications beyond pulmonary embolism.

GCM Corporation is advancing its commercialisation strategy with multiple prototypes across key global markets and sectors, aiming for revenue in the first half of 2026.